40.14

5.68% 2.19

Celldex Therapeutics Inc (CLDX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$37.95

Offen:

$38.13

24-Stunden-Volumen:

754.49K

Relative Volume:

0.73

Marktkapitalisierung:

$3.15B

Einnahmen:

$1.55M

Nettoeinkommen (Verlust:

$-258.76M

KGV:

-10.30

EPS:

-3.8953

Netto-Cashflow:

$-213.66M

1W Leistung:

+7.78%

1M Leistung:

+40.13%

6M Leistung:

+44.47%

1J Leistung:

+91.16%

1-Tages-Spanne:

$37.30

$40.19

1-Wochen-Bereich:

$36.17

$40.19

52-Wochen-Spanne:

$19.72

$40.19

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Firmenname

Celldex Therapeutics Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

908-200-7500

Adresse

53 FRONTAGE ROAD, HAMPTON

Mitarbeiter

198

Twitter

@search?q=celldex

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

CLDX's Discussions on Twitter

Compare CLDX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CLDX Celldex Therapeutics Inc	40.10	3.01B	1.55M	-258.76M	-213.66M	-3.8953
VRTX Vertex Pharmaceuticals Inc	524.31	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.45	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	921.42	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.25	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.81	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-20	Hochstufung	Barclays	Underweight → Overweight
2026-03-23	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-10-21	Eingeleitet	Mizuho	Outperform
2025-10-13	Eingeleitet	Barclays	Underweight
2025-04-28	Eingeleitet	Canaccord Genuity	Buy
2025-03-20	Eingeleitet	Morgan Stanley	Overweight
2025-02-13	Eingeleitet	UBS	Buy
2024-10-07	Eingeleitet	Citigroup	Buy
2024-09-30	Eingeleitet	Goldman	Neutral
2024-09-27	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-18	Eingeleitet	Stifel	Buy
2024-06-11	Eingeleitet	Wolfe Research	Outperform
2023-12-20	Eingeleitet	TD Cowen	Outperform
2023-11-10	Hochstufung	Wells Fargo	Underweight → Equal Weight
2023-08-22	Eingeleitet	Wells Fargo	Underweight
2021-09-17	Eingeleitet	Jefferies	Buy
2021-09-10	Eingeleitet	SVB Leerink	Outperform
2021-07-22	Eingeleitet	Guggenheim	Buy
2020-02-21	Eingeleitet	Cantor Fitzgerald	Overweight
2017-08-01	Fortgesetzt	H.C. Wainwright	Buy
2016-11-07	Eingeleitet	Aegis Capital	Buy
2016-03-08	Herabstufung	Jefferies	Buy → Hold
2016-03-07	Herabstufung	Guggenheim	Buy → Neutral
2016-03-07	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2016-03-07	Herabstufung	Wedbush	Outperform → Neutral
2016-03-01	Eingeleitet	H.C. Wainwright	Buy
2015-08-11	Bestätigt	Brean Capital	Buy
2015-08-11	Bestätigt	Oppenheimer	Outperform
2015-08-11	Bestätigt	ROTH Capital	Buy
2015-06-02	Bestätigt	WBB Securities	Strong Buy
2014-11-17	Bestätigt	ROTH Capital	Buy
2014-03-04	Bestätigt	Oppenheimer	Outperform
2013-07-08	Bestätigt	Cantor Fitzgerald	Buy
2013-03-08	Bestätigt	Cantor Fitzgerald	Buy
2013-02-26	Bestätigt	Oppenheimer	Outperform
2013-01-10	Bestätigt	Cantor Fitzgerald	Buy
2012-10-02	Bestätigt	Oppenheimer	Outperform
2012-09-14	Bestätigt	Cantor Fitzgerald	Buy

Alle ansehen

Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten

09:25 AM

Price to sales forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView

09:25 AM

Jul 05, 2026

Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed? - simplywall.st

Jul 05, 2026

Jul 02, 2026

Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus - Sahm

Jul 02, 2026

Jul 01, 2026

CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 01, 2026

Jun 30, 2026

Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $54 - Moomoo

Jun 30, 2026

CLDX Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Pipeline ProgressEarnings Season Review - dars.gov.et

Jun 30, 2026

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval? - Yahoo Finance

Jun 30, 2026

Jun 29, 2026

Form 4 Celldex Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 29, 2026

Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Celldex (NASDAQ: CLDX) CCO granted 90,000 stock options at $34.09 - Stock Titan

Jun 29, 2026

Celldex (NASDAQ: CLDX) grants SVP & counsel 93,000 stock options - Stock Titan

Jun 29, 2026

Celldex (CLDX) CMO Diane Young receives 57,000 stock options grant - Stock Titan

Jun 29, 2026

Celldex (CLDX) SVP granted 95,000 options at $34.09 strike - Stock Titan

Jun 29, 2026

Celldex Therapeutics (CLDX) CFO awarded 93,000 stock options grant - Stock Titan

Jun 29, 2026

Celldex (CLDX) SVP awarded 95,000-share stock option grant at $34.09 - Stock Titan

Jun 29, 2026

Celldex (NASDAQ: CLDX) grants 100,000 options to senior VP & CPDO - Stock Titan

Jun 29, 2026

Celldex Therapeutics (CLDX) grants 20,000 stock options to senior VP - Stock Titan

Jun 29, 2026

Celldex (CLDX) EVP & CSO awarded 115,000-share stock option grant - Stock Titan

Jun 29, 2026

Celldex (CLDX) CEO Anthony Marucci receives grant of 375,000 stock options - Stock Titan

Jun 29, 2026

Celldex (CLDX) director awarded 26,000-share stock option grant as compensation - Stock Titan

Jun 29, 2026

Celldex (CLDX) director receives grant of 26,000 stock options - Stock Titan

Jun 29, 2026

Celldex (CLDX) director James Marino awarded options on 26,000 shares - Stock Titan

Jun 29, 2026

Celldex Therapeutics (CLDX) director receives grant of 26,000 stock options - Stock Titan

Jun 29, 2026

Celldex (CLDX) director receives 26,000 stock options under 2021 incentive plan - Stock Titan

Jun 29, 2026

Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Celldex Therapeutics stock hits 52-week high at 35.8 USD - Investing.com

Jun 29, 2026

Celldex Therapeutics stock hits 52-week high at 35.8 USD By Investing.com - Investing.com South Africa

Jun 29, 2026

Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 28, 2026

Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026

Enterprise value to EBIT forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView

Jun 28, 2026

5 Best Biotech Stocks to Buy According to Analysts - Insider Monkey

Jun 28, 2026

Enterprise value to EBIT forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView

Jun 28, 2026

Jun 27, 2026

Price to earnings forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView

Jun 27, 2026

Price to book forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView

Jun 27, 2026

Jun 26, 2026

Celldex Shareholders Approve Expanded Equity Incentive Plan - TipRanks

Jun 26, 2026

Celldex (CLDX) shareholders back larger equity plan and all directors - Stock Titan

Jun 26, 2026

Celldex Therapeutics (CLDX) Is Up 5.1% After Barzolvolimab, CDX-622 Mast-Cell Data UpdateWhat's Changed - Sahm

Jun 26, 2026

Celldex Therapeutics, Inc. Actuals & Estimates (NASDAQ:CLDX) - TradingView

Jun 26, 2026

Jun 25, 2026

CLDX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight - PR Newswire

Jun 24, 2026

Jun 19, 2026

Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data - Sahm

Jun 19, 2026

Jun 18, 2026

Chronic Spontaneous Urticaria Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart

Jun 18, 2026